Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methoxy polyethylene glycol-epoetin beta - Roche

Drug Profile

Methoxy polyethylene glycol-epoetin beta - Roche

Alternative Names: CERA-pegylated-epoetin-beta; Continuous-erythropoietin-receptor-activator-pegylated-epoetin-beta; Epoetin beta pegol; Mircera; R-744; RO-0503821; RO-50-3821

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche; Vifor Pharma
  • Class Antianaemics; Colony-stimulating factors; Erythropoietins; Haematopoietic cell growth factors; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia
  • Discontinued Chemotherapy-induced anaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Jun 2018 Registered for Anaemia (In children, In adolescents) in USA (IV)
  • 06 Apr 2018 Phase-II clinical trials in Anaemia (In adolescents, In children, In infants) in Spain, Poland (SC) (NCT03552393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top